This article was originally published in The Gray Sheet
Executive SummaryCompletes a $4.8 mil. equity financing, which the firm will use for working capital. Six venture capital investors, including the firm's three initial backers, provided funding for the deal. PSI has also reached a $750,000 debt financing agreement with Connecticut Innovations, which is part of the Connecticut Department of Economic Development. In November 1992, PSI began international marketing of its EMI-Lith intracorporeal lithotripsy system, which is comprised of fragmentation, irrigation and vision systems. The Shelton, Connecticut-based firm sells the system for approximately $55,000 and has received approximately $1 mil. in overseas orders since marketing began. The company currently is responding to FDA questions about a component of the fragmentation system, the EMI probe, for which the firm submitted a 510(k) in January 1992. PSI also is awaiting FDA clearance of its Flo-Mate hand pump, a component of EMI-Lith's vision segment. PSI submitted a 510(k) for the device in December 1991.
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.
Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.